The effect of Chitosan IFNα-pDNA Nanoparticle on the Pain induced by Varicella-zoster Virus in a Rat Model of Post-Herpetic Neuralgia
DOI:
https://doi.org/10.46966/msjar.v6i4.338Keywords:
Chitosan IFNα-pDNA Nanoparticle, varicella-zoster virus, post-herpetic neuralgiaAbstract
Background and Aim: Acute and chronic pain (post-herpetic neuralgia or PHN) are encountered in patients with herpes zoster that is caused by reactivation of varicella-zoster virus (VZV) from a state of neuronal latency. PHN is often refractory to current treatments, and additional strategies for pain relief are needed. The present study aims to assess the effects of Chitosan IFNα-pDNA Nanoparticle(CIN) on the pain induced by varicella-zoster virus in Sprague–Dawley rat model of post-herpetic neuralgia. Methods: : Rats were injected with 0.2mL of PBS, Chitosan IFNα-pDNA Nanoparticle( dose corresponding to 50μg pDNA in 1mL) and IFNα-pDNA(50μg/mL) 3 days before VZV infection. MA and TH ipsilateral/contralateral responses were measured according to days after VZV infection. And also rats inoculated with VZV and showing significant mechanical and thermal hypersensitivity by 19 days post infection were then inoculated at the same footpad with 0.2mL of PBS, Chitosan IFNα-pDNA Nanoparticle( dose corresponding to 50μg pDNA in 1mL) and IFNα-pDNA(50μg/mL). Animals receiving PBS, Chitosan IFNα-pDNA Nanoparticle(CIN) and IFNα-pDNA continued to measure MA and TH ipsilateral/contralateral responses according to days after vector administration. Results: Chitosan IFNα-pDNA Nanoparticle(CIN) effectively reduced chronic VZV-induced nocifensive indicators of pain such as mechanical allodynia(MA), thermal hyperalgesia (TH). Conclusion: These results indicate that administration of Chitosan IFNα-pDNA Nanoparticle(CIN) relieved VZV-induced pain and prophylactic CIN administration prevented VZV-induced pain from developing.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Hyok Ho Jon, Song Chan Han, Sinhyok Paek, Sungil Paek, Songchol Mun
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
